A method for modulating an immune response by activating or inhibiting dopaminergic neurons in the Ventral Tegmental Area (VTA) is provided. Modulation is achieved by modulating the activity, the abundance or both of: a natural killer cell, a CD8 T-cell, a CD4 T-cell, a B-cell, a dendritic cell, a macrophage, a granulocyte, or their combination.

A method for modulating an immune response by activating or inhibiting dopaminergic neurons in the Ventral Tegmental Area (VTA) is provided. Modulation is achieved by modulating the activity, the abundance or both of: a natural killer cell, a CD8 T-cell, a CD4 T-cell, a B-cell, a dendritic cell, a macrophage, a granulocyte, or their combination.

The invention relates to aboveground plant parts of Sideritis ssp. or extracts produced therefrom for use to boost cognitive performance.

The invention relates to aboveground plant parts of Sideritis ssp. or extracts produced therefrom for use to boost cognitive performance.

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.

##STR00001##

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.

##STR00001##

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.

##STR00001##

The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR 1)modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.

The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR 1)modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.

The present application provides the use of an acridinedione compound in the preparation of an antidiabetic medicament, which belongs to the field of biomedical technology. The present application demonstrates for the first time that the acridinedione compound can improve insulin resistance by activating and upregulating GPR40 protein expression, participating in GPR40-PPARγ-PI3K/Akt-GLUT4 signaling pathway, promoting insulin secretion and increasing glucose consumption in liver and muscle tissue. The target of the acridinedione compound is the GPR40 receptor, its insulinotropic effect is glucose-dependent, and its hypoglycemic effect disappears when peripheral blood glucose falls below a certain level. The preparation of the acridinedione compound into an antidiabetic medicaments will provide entirely new options and strategies for the treatment of diabetes.